CN101321528B - 治疗增殖性疾病或炎症的3,11b-顺式-二氢丁苯那嗪 - Google Patents

治疗增殖性疾病或炎症的3,11b-顺式-二氢丁苯那嗪 Download PDF

Info

Publication number
CN101321528B
CN101321528B CN2006800366007A CN200680036600A CN101321528B CN 101321528 B CN101321528 B CN 101321528B CN 2006800366007 A CN2006800366007 A CN 2006800366007A CN 200680036600 A CN200680036600 A CN 200680036600A CN 101321528 B CN101321528 B CN 101321528B
Authority
CN
China
Prior art keywords
dihydrotetrabenazine
isomer
cis
isomers
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800366007A
Other languages
English (en)
Chinese (zh)
Other versions
CN101321528A (zh
Inventor
A·J·杜菲尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valeant Laboratories International Bermuda SRL
Original Assignee
Biovail Laboratories International Barbados SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovail Laboratories International Barbados SRL filed Critical Biovail Laboratories International Barbados SRL
Publication of CN101321528A publication Critical patent/CN101321528A/zh
Application granted granted Critical
Publication of CN101321528B publication Critical patent/CN101321528B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2006800366007A 2005-08-05 2006-08-04 治疗增殖性疾病或炎症的3,11b-顺式-二氢丁苯那嗪 Expired - Fee Related CN101321528B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0516168.2A GB0516168D0 (en) 2005-08-05 2005-08-05 Pharmaceutical compounds
GB0516168.2 2005-08-05
PCT/GB2006/002909 WO2007017643A1 (en) 2005-08-05 2006-08-04 3 , llB-CIS-DIHYDROTETRABENAZINE FOR THE TREATMENT OF A PROLIFERATIVE DISEASE OR AN INFLAMMATION

Publications (2)

Publication Number Publication Date
CN101321528A CN101321528A (zh) 2008-12-10
CN101321528B true CN101321528B (zh) 2011-05-25

Family

ID=34984180

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800366007A Expired - Fee Related CN101321528B (zh) 2005-08-05 2006-08-04 治疗增殖性疾病或炎症的3,11b-顺式-二氢丁苯那嗪

Country Status (23)

Country Link
US (1) US20090275605A1 (enExample)
EP (2) EP1861100B1 (enExample)
JP (1) JP2009503045A (enExample)
KR (1) KR20080033501A (enExample)
CN (1) CN101321528B (enExample)
AT (1) ATE412414T1 (enExample)
AU (1) AU2006277836B8 (enExample)
CA (1) CA2620952A1 (enExample)
CY (1) CY1108729T1 (enExample)
DE (1) DE602006003415D1 (enExample)
DK (1) DK1861100T3 (enExample)
ES (1) ES2317564T3 (enExample)
GB (1) GB0516168D0 (enExample)
HR (1) HRP20090017T3 (enExample)
MX (1) MX2008001546A (enExample)
NZ (1) NZ566010A (enExample)
PL (1) PL1861100T3 (enExample)
PT (1) PT1861100E (enExample)
RS (1) RS50720B (enExample)
RU (1) RU2409364C2 (enExample)
SI (1) SI1861100T1 (enExample)
WO (1) WO2007017643A1 (enExample)
ZA (2) ZA200801171B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
GB0514501D0 (en) * 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
AU2007317242B2 (en) 2006-11-08 2013-08-01 Neurocrine Biosciences, Inc. Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto
GB0721669D0 (en) * 2007-11-02 2007-12-12 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463451A (en) 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
WO2011153157A2 (en) 2010-06-01 2011-12-08 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
CN102285984B (zh) * 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
MX2016009817A (es) 2014-01-27 2017-02-28 Auspex Pharmaceuticals Inc Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2.
MA41177A (fr) * 2014-12-15 2017-10-24 Esteve Labor Dr Utilisation de ligands des récepteurs sigma dans l'arthrose
US10550120B2 (en) 2016-03-25 2020-02-04 Tohoku University Indole alkaloid compound having immune checkpoint inhibitory action
CN109283279B (zh) * 2017-07-21 2019-11-01 南京正大天晴制药有限公司 通过高效液相色谱法分离测定雷替曲塞及其对映异构体的方法
CN109283263B (zh) * 2017-07-21 2019-06-25 南京正大天晴制药有限公司 用于雷替曲塞合成质量控制的检测分析方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077946A1 (en) * 2004-02-11 2005-08-25 Cambridge Laboratories (Ireland) Limited Dihydrotetrabenazines and pharmaceutical compositions containing them

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3314966A (en) * 1967-04-18 Substituted benzo[a]quinolizines
US2843591A (en) * 1958-07-15 Method for preparing same
US3132147A (en) * 1964-05-05
US3209005A (en) * 1965-09-28 Hexahydro-llbh-benzo[a] quinolizines and processes therefor
US3079395A (en) * 1963-02-26 Novel z-oxq-benzoquinoliaine
US2830993A (en) * 1958-04-15 Quinolizine derivatives
US3159638A (en) * 1964-12-01 Xcha-chj
US2954382A (en) * 1960-09-27 Xpreparation of hexahydrobenzoquinol-
US3009918A (en) * 1961-11-21 Chz ch
US3095419A (en) * 1963-06-25 Process for preparing z-oxo-j-
US3053845A (en) * 1962-09-11 Benzofykedocolines
US3123609A (en) * 1964-03-03 Benzo
US3045021A (en) * 1959-09-24 1962-07-17 Hoffmann La Roche Preparation of substituted 2-oxobenzoquinolizines
GB999092A (en) * 1959-11-24 1965-07-21 Wellcome Found Method for making benzo(a)-quinolizine derivatives
US3375254A (en) * 1961-09-29 1968-03-26 Burroughs Wellcome Co Manufacture of 1, 2, 3, 4, 6, 7-hexahydro-2-oxo-11bh-benzo(a)quinolizines
US3105079A (en) * 1961-12-29 1963-09-24 Pfizer & Co C 10-aminobenzopyridocolines
US3390152A (en) * 1965-10-21 1968-06-25 Abbott Lab 9, 10-alkoxy-3-alkyl-2, 2-(dithiosubstituted)-benzoquinolizines
US3634431A (en) * 1969-12-22 1972-01-11 Miles Lab Acylated and alkylated derivatives of 2-aminohexahydrobenzo(a)quinolizines
US3635986A (en) * 1969-12-22 1972-01-18 Miles Lab 2-substituted amino-hexahydrobenzo(a)quinolizines
YU264675A (en) * 1974-10-23 1982-05-31 Chinoin Gyogyszer Es Vegyeszet Process for obtaining benzo (a)-quinolizidine derivatives
GB1513824A (en) * 1975-05-22 1978-06-14 Wyeth John & Brother Ltd 1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizine derivative
US4133812A (en) * 1975-11-21 1979-01-09 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Process for producing benzo (a) quinolizine derivatives
US4304913A (en) * 1978-11-20 1981-12-08 Miles Laboratories, Inc. Trans-2-substituted-amido-hexahydrobenzo [A]quinolizines
US4353656A (en) * 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
AT396872B (de) * 1985-07-30 1993-12-27 Glaxo Group Ltd Gerät zur verabreichung von medikamenten in pulverform
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2794742B1 (fr) * 1999-06-11 2005-06-03 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
US6632666B2 (en) * 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
CA2398446A1 (en) * 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinases
CA2529746C (en) * 2003-06-16 2010-08-03 Andrx Pharmaceuticals, Llc Oral extended-release composition
KR100682506B1 (ko) * 2005-01-18 2007-02-15 (주)젠크로스 프라지콴텔, 또는 이의 염을 포함하는 약학 조성물
GB0514501D0 (en) * 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077946A1 (en) * 2004-02-11 2005-08-25 Cambridge Laboratories (Ireland) Limited Dihydrotetrabenazines and pharmaceutical compositions containing them

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Mehvar R, Jamali F.Concentration -effect relationships of tetrabenzaine anddihydrotetrabenazine in the rat.Journal of Pharmaceutical Sciences76 6.1987,76(6),461-465.
Mehvar R, Jamali F.Concentration-effect relationships of tetrabenzaine anddihydrotetrabenazine in the rat.Journal of Pharmaceutical Sciences76 6.1987,76(6),461-465. *
Schaefer A et. al.Effects of biogenic amines and psychotropic drugs onendogenous prostaglandin biosynthesis in the rat brainhomogenates.Biochemical Pharmacology27 2.1978,27(2),213-218.
Schaefer A et. al.Effects of biogenic amines and psychotropic drugs onendogenous prostaglandin biosynthesis in the rat brainhomogenates.Biochemical Pharmacology27 2.1978,27(2),213-218. *

Also Published As

Publication number Publication date
PT1861100E (pt) 2008-12-26
ZA200801170B (en) 2009-12-30
RU2409364C2 (ru) 2011-01-20
PL1861100T3 (pl) 2009-06-30
CN101321528A (zh) 2008-12-10
AU2006277836A1 (en) 2007-02-15
KR20080033501A (ko) 2008-04-16
EP1861100B1 (en) 2008-10-29
CY1108729T1 (el) 2014-04-09
CA2620952A1 (en) 2007-02-15
GB0516168D0 (en) 2005-09-14
RS50720B (sr) 2010-08-31
DE602006003415D1 (de) 2008-12-11
NZ566010A (en) 2010-05-28
MX2008001546A (es) 2008-04-04
EP1964565A1 (en) 2008-09-03
DK1861100T3 (da) 2008-12-15
WO2007017643A1 (en) 2007-02-15
EP1861100A1 (en) 2007-12-05
JP2009503045A (ja) 2009-01-29
US20090275605A1 (en) 2009-11-05
HK1111084A1 (en) 2008-08-01
RU2008108516A (ru) 2009-09-10
AU2006277836B8 (en) 2011-12-08
ZA200801171B (en) 2009-08-26
ATE412414T1 (de) 2008-11-15
HRP20090017T3 (hr) 2009-03-31
SI1861100T1 (sl) 2009-04-30
AU2006277836B2 (en) 2011-11-10
ES2317564T3 (es) 2009-04-16

Similar Documents

Publication Publication Date Title
CN101321528B (zh) 治疗增殖性疾病或炎症的3,11b-顺式-二氢丁苯那嗪
JP7054529B2 (ja) Ｃｘｃｒ４阻害剤およびその使用
JP7348906B2 (ja) フェロトーシス誘導活性を有する化合物およびそれらの使用方法
CN114867530B (zh) Mcl1抑制剂
JP6920295B2 (ja) テトラヒドロナフタレンエストロゲン受容体モジュレーター及びその使用
CN119487038A (zh) Kras g12d调节化合物
JP2021185195A (ja) Ｃｘｃｒ４阻害剤およびその使用
US11952349B2 (en) Anti-cancer nuclear hormone receptor-targeting compounds
EP3999507B1 (en) Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonsits
TWI834655B (zh) 特定芳基普拉二烯內酯化合物及其使用方法
WO2016022955A1 (en) Compounds and methods for treating cancer
US20100226917A1 (en) Methods for the treatment of hematologic malignancies
EP3570824A1 (en) Compositions and methods for controlling natural killer cell activation and function
KR102805214B1 (ko) Mll1 억제제 및 항암제
HK1121405A (en) 3,11b-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation
EP4441052B1 (en) Compounds
US20240140947A1 (en) Compound for the treatment of cancer
JP2020505378A (ja) 新規化合物（イムノヘリン−細胞内感染）
HK40078523A (en) Mcl1 inhibitors
HK40078523B (zh) Mcl1抑制剂
JP2025508983A (ja) 重水素化レチノイド化合物ならびにその合成および使用
TW201307330A (zh) 治療乳腺癌之藥物組合
HK1111084B (en) 3,11b-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation
JP2017214367A (ja) 悪性リンパ腫の処置用の医薬組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: BIOVAIL LABORATORY INTERNATIONAL (BARBADOS) CO., L

Free format text: FORMER OWNER: CAMBRIDGE LAB IRELAND LTD.

Effective date: 20100919

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: DUBLIN, IRELAND TO: BARBADOS ARBADOS

TA01 Transfer of patent application right

Effective date of registration: 20100919

Address after: Barbados

Applicant after: Biovail Lab Internat Barbados SRL

Address before: Dublin, Ireland

Applicant before: Cambridge laboratories (Ireland) Ltd

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110525

Termination date: 20120804